Alpha Capital Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-12,223
| Closed | -$416K | – | 117 |
|
|
2025
Q1 | $416K | Buy |
+12,223
| New | +$416K | 0.08% | 94 |
|
|
2024
Q3 | – | Sell |
-36,636
| Closed | -$1.98M | – | 112 |
|
|
2024
Q2 | $1.98M | Sell |
36,636
-7,610
| -17% | -$411K | 0.39% | 65 |
|
|
2024
Q1 | $3.02M | Sell |
44,246
-492
| -1% | -$33.5K | 0.59% | 63 |
|
|
2023
Q4 | $2.8M | Sell |
44,738
-1,411
| -3% | -$88.3K | 0.58% | 62 |
|
|
2023
Q3 | $2.09M | Buy |
46,149
+13,208
| +40% | +$600K | 0.49% | 66 |
|
|
2023
Q2 | $1.34M | Hold |
32,941
| – | – | 0.33% | 74 |
|
|
2023
Q1 | $1.34M | Hold |
32,941
| – | – | 0.33% | 74 |
|
|
2022
Q4 | $1.34M | Buy |
32,941
+2,823
| +9% | +$115K | 0.33% | 74 |
|
|
2022
Q3 | $1.97M | Buy |
30,118
+3,213
| +12% | +$210K | 0.52% | 67 |
|
|
2022
Q2 | $1.64M | Buy |
26,905
+3,581
| +15% | +$218K | 0.45% | 68 |
|
|
2022
Q1 | $1.46M | Buy |
23,324
+852
| +4% | +$53.5K | 0.32% | 73 |
|
|
2021
Q4 | $1.7M | Sell |
22,472
-2,419
| -10% | -$183K | 0.38% | 70 |
|
|
2021
Q3 | $2.79M | Sell |
24,891
-569
| -2% | -$63.7K | 0.66% | 54 |
|
|
2021
Q2 | $4.12M | Buy |
25,460
+17,118
| +205% | +$2.77M | 0.97% | 30 |
|
|
2021
Q1 | $1.02M | Buy |
8,342
+3,164
| +61% | +$385K | 0.26% | 79 |
|
|
2020
Q4 | $793K | Buy |
+5,178
| New | +$793K | 0.2% | 79 |
|